Some Apolipoproteins Linked to Incident Type 2 Diabetes

Share this content:
Some Apolipoproteins Linked to Incident Type 2 Diabetes
Some Apolipoproteins Linked to Incident Type 2 Diabetes

THURSDAY, Jan. 5, 2017 (HealthDay News) -- Apolipoprotein (apo) CIII and apoCIII-to-apoA1 ratio are correlated with incident type 2 diabetes (T2D), according to a study published online Dec. 28 in Diabetes Care.

Adela Brahimaj, M.D., from the Erasmus University Medical Center in Rotterdam, Netherlands, and colleagues used data from 971 individuals from the prospective population-based Rotterdam Study to examine the role of apolipoproteins on the risk for T2D. They examined the correlation of high-density lipoprotein cholesterol (HDL-C), apoA1, apoCIII, apoD, and apoE and the ratios of apolipoproteins with apoA1 with T2D risk.

The researchers found that during a median follow-up of 13.5 years, 110 individuals developed diabetes. HDL-C, apoCIII, apoE, apoCIII-to-apoA1 ratio, apoE-to-apoA1 ratio, and apolipoproteinic score remained significant after adjustment for age, sex, body mass index, parental history of diabetes, hypertension, alcohol use, smoking, prevalent cardiovascular disease, and serum lipid-reducing agents (per one standard deviation naturally log-transformed hazard ratios, 0.74, 1.65, 1.36, 1.72, 1.28, and 1.6, respectively). After adjustment for triglycerides in the last model, only apoCIII and apoCIII-to-apoA1 ratio remained significant (hazard ratios, 1.42 and 1.56, respectively).

"Serum apoCIII levels as well as apoCIII-to-apoA1 ratio are associated with incident T2D," the authors write. "They are associated independent of known risk factors and stronger than HDL-C levels."

One author disclosed financial ties to the nutrition and lifestyle industries.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »